NCT02890355 2026-03-05
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Mayo Clinic
University of Nebraska
Albert Einstein College of Medicine
University of Nebraska
Northwestern University